NCT01345851View on ClinicalTrials.gov

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NAActive, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 23, 2011

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Adenocarcinoma of the LungAdenosquamous Cell Lung CancerLarge Cell Lung CancerRecurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IIA Non-small Cell Lung CancerStage IIB Non-small Cell Lung CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung Cancer
Interventions
RADIATION

hypofractionated radiation therapy

Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks

OTHER

laboratory biomarker analysis

Correlative studies

RADIATION

image-guided radiation therapy

Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.

DRUG

carboplatin

The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.

DRUG

paclitaxel

The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.

RADIATION

stereotactic body radiation therapy

Undergo hypofractionated RT

Trial Locations (1)

90095

Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT01345851 - Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter